Barallobre-Barreiro Javier, Chung Yuen-Li, Mayr Manuel
King's British Heart Foundation Centre, King's College of London, London, United Kingdom.
Cancer Research UK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.
Rev Esp Cardiol (Engl Ed). 2013 Aug;66(8):657-61. doi: 10.1016/j.rec.2013.04.009. Epub 2013 Jul 2.
In the last decade, proteomics and metabolomics have contributed substantially to our understanding of cardiovascular diseases. The unbiased assessment of pathophysiological processes without a priori assumptions complements other molecular biology techniques that are currently used in a reductionist approach. In this review, we highlight some of the "omics" methods used to assess protein and metabolite changes in cardiovascular disease. A discrete biological function is very rarely attributed to a single molecule; more often it is the combined input of many proteins. In contrast to the reductionist approach, in which molecules are studied individually, "omics" platforms allow the study of more complex interactions in biological systems. Combining proteomics and metabolomics to quantify changes in metabolites and their corresponding enzymes will advance our understanding of pathophysiological mechanisms and aid the identification of novel biomarkers for cardiovascular disease.
在过去十年中，蛋白质组学和代谢组学极大地促进了我们对心血管疾病的理解。在没有先验假设的情况下对病理生理过程进行无偏评估，补充了目前以还原论方法使用的其他分子生物学技术。在本综述中，我们重点介绍了一些用于评估心血管疾病中蛋白质和代谢物变化的“组学”方法。一种离散的生物学功能很少归因于单个分子；更多时候是许多蛋白质的综合作用。与逐个研究分子的还原论方法不同，“组学”平台允许研究生物系统中更复杂的相互作用。将蛋白质组学和代谢组学结合起来以量化代谢物及其相应酶的变化，将增进我们对病理生理机制的理解，并有助于识别心血管疾病的新型生物标志物。
